Evidence that different mechanisms underlie smooth muscle relaxation to nitric oxide and nitric oxide donors in the rabbit isolated carotid artery

被引:71
|
作者
Plane, F
Wiley, KE
Jeremy, JY
Cohen, RA
Garland, CJ
机构
[1] Univ Bristol, Dept Pharmacol, Bristol BS8 1TD, Avon, England
[2] Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England
[3] Boston Univ, Med Ctr, Vasc Biol Unit, Boston, MA 02118 USA
基金
英国惠康基金;
关键词
nitric oxide; smooth muscle relaxation; potassium channels;
D O I
10.1038/sj.bjp.0701746
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The endothelium-dependent relaxants acetylcholine (ACh; 0.03 - 10 mu M) and A23187 (0.03 - 10 mu M), and nitric oxide (NO), applied either as authentic NO (0.01-10 mu M) or as the NO donors 3-morpholinosydnonimine (SIN-1; 0.1-10 mu M) and S-nitroso-N-acetylpenicillamine (SNAP; 0.1-10 mu M), each evoked concentration-dependent relaxation in phenylephrine stimulated (1-3 mu M; mean contraction and depolarization, 45.8 +/- 5.3 mV and 31.5 +/- 3.3 mN; n = 10) segments of rabbit isolated carotid artery. In each case, relaxation closely correlated with repolarization of the smooth muscle membrane potential and stimulated a maximal reversal of around 95% and 98% of the phenylephrine-induced depolarization and contraction, respectively. 2 In tissues stimulated with 30 mM KCI rather than phenylephrine, smooth muscle hyperpolarization and relaxation to ACh, A23187, authentic NO and the NO donors were dissociated. Whereas the hyperpolarization was reduced by 75-80% to around a total of 10 mV, relaxation was only inhibited by 35% (n = 4-7 in each case; P < 0.01). The responses which persisted to ACh and A23187 in the presence of 30 mM KCl were abolished by either the NO synthase inhibitor L-N-G-nitroarginine methyl ester (L-NAME; 100 mu M) or the inhibitor of soluble guanylyl cyclase 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 10 mu M; 10 min; n = 4 in each case; P < 0.01). 3 Exposure to ODQ significantly attenuated both repolarization and relaxation to ACh, A23187 and authentic NO, reducing the maximum changes in both membrane potential and tension to each relaxant to around 60% of control values (n = 4 in each case; P < 0.01). In contrast, ODQ almost completely inhibited repolarization and relaxation to SIN-1 and SNAP, reducing the maximum responses to around 8% in each case (n = 3-5; P < 0.01). 4 The potassium channel blockers glibenclamide (10 mu M), iberiotoxin (100 nM) and apamin (50 nM), alone or in combination, had no significant effect on relaxation to ACh, A23187, authentic NO, or the NO donors SIN-1 and SNAP (n = 4 in each case; P > 0.05). Charybdotoxin (ChTX; 50 nM) almost abolished repolarization to ACh (n = 4; P < 0.01) and inhibited the maximum relaxation to ACh, A23187 and authentic NO each by 30% (n = 4-8; P < 0.01). Application of ODQ (10 mu M; 10 min) abolished the ChTX-insensitive responses to ACh, A23187 and authentic NO (n = 4 in each case; P<0.01 5 When the concentration of phenylephrine was reduced (to 0.3-0.5 mu M) to ensure the level of smooth muscle contraction was the same as in the absence of potassium channel blocker, ChTX had no effect on the subsequent relaxation to SIN-1 (n = 4; P > 0.05). However, in the presence of tone induced by 1-3 mu M phenylephrine (51.2 +/- 3.3 mN; n = 4), ChTX significantly reduced relaxation to SIN-1 by nearly 50% (maximum relaxation 53.2 +/- 6.3%, n = 4; P < 0.01). 6 These data indicate that NO-evoked relaxation of the rabbit isolated carotid artery can be mediated by three distinct mechanisms: (a) a cyclic GMP-dependent, voltage-independent pathway, (b) cyclic GMP-mediated smooth muscle repolarization and (c) cyclic GMP-independent, ChTX-sensitive smooth muscle repolarization. Relaxation and repolarization to both authentic and endothelium-derived NO in this large conduit artery appear to be mediated by parallel cyclic GMP-dependent and -independent pathways. In contrast, relaxation to the NO-donors SIN-1 and SNAP appears to be mediated entirely via cyclic GMP-dependent mechanisms.
引用
收藏
页码:1351 / 1358
页数:8
相关论文
共 50 条
  • [21] Nitric oxide donors for peripheral artery disease
    Falconer, Debbie
    Papageorgiou, Nikolaos
    Salem, Karim
    Lim, Wei Yao
    Katsargyris, Athanasios
    Avgerinos, Efthimios
    Tousoulis, Dimitris
    CURRENT OPINION IN PHARMACOLOGY, 2018, 39 : 77 - 85
  • [22] Nitric oxide inhibits contraction of isolated pig ureteral smooth muscle
    Iselin, CE
    Alm, P
    Schaad, NC
    Larsson, B
    Graber, P
    Andersson, KE
    JOURNAL OF UROLOGY, 1996, 155 (02): : 763 - 767
  • [23] Central application of nitric oxide (NO) donors activates heat defense mechanisms in the rabbit
    Hjelmqvist, H
    Eriksson, S
    Keil, R
    Gerstberger, R
    FASEB JOURNAL, 1997, 11 (03): : 516 - 516
  • [24] Autoinhibition of endothelial nitric oxide synthase (eNOS) in gut smooth muscle by nitric oxide
    Grider, John R.
    Murthy, Karnam S.
    REGULATORY PEPTIDES, 2008, 151 (1-3) : 75 - 79
  • [25] MECHANISMS OF INHIBITION OF SMOOTH-MUSCLE PROLIFERATION BY NITRIC-OXIDE (NO)
    SARKAR, R
    STANLEY, JC
    WEBB, RC
    HYPERTENSION, 1995, 26 (03) : 543 - 543
  • [26] MECHANISMS OF NITRIC-OXIDE REGULATION OF SMOOTH-MUSCLE CONTRACTION
    JONES, KA
    WONG, GY
    JANKOWSKI, CJ
    WARNER, DO
    ANESTHESIOLOGY, 1995, 83 (3A) : A1208 - A1208
  • [27] Modulation by endothelial nitric oxide of sympathetic neuroeffector transmission in the rabbit carotid artery
    Jensen, TJ
    Nedergaard, OA
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R301 - R301
  • [28] Cellular mechanisms of nitric oxide-induced relaxation of corporeal smooth muscle in the guinea-pig
    Hashitani, H
    Fukuta, H
    Dickens, EJ
    Suzuki, H
    JOURNAL OF PHYSIOLOGY-LONDON, 2002, 538 (02): : 573 - 581
  • [29] EVIDENCE FOR NITRIC-OXIDE AS THE INHIBITORY NEUROTRANSMITTER IN ISOLATED RABBIT ANOCOCCYGEUS
    GRAHAM, AM
    SNEDDON, P
    BRITISH JOURNAL OF PHARMACOLOGY, 1992, 106 : P22 - P22
  • [30] EVIDENCE FOR NITRIC-OXIDE AS AN INHIBITORY NEUROTRANSMITTER IN RABBIT ISOLATED ANOCOCCYGEUS
    GRAHAM, AM
    SNEDDON, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 237 (01) : 93 - 99